Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.
Mimidis
Konstantinos
K
First Department of Internal Medicine, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
Tsatalas
Costas
C
Margaritis
Dimitris
D
Martinis
George
G
Spanoudakis
Emanuel
E
Kotsiou
Stamatia
S
Kartalis
George
G
Bourikas
George
G
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D004279:DNA, Viral / Q000097:blood; D005188:False Negative Reactions; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006513:Hepatitis B e Antigens / Q000097:blood / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency
D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine